Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort

By sjmartinez • April 10, 2025

Davies Smith E, Malvestutto C, Ribaudo HJ, Fichtenbaum CJ, Aberg JA, Watanabe M, Bloomfield GS, Currier JS, Chu SM, Fitch KV, Diggs MR, Bedimo R, Valencia J, Gomez-Ayerbe C, Brar I, Madruga JV, Lu MT, Douglas PS, Zanni MV, Grinspoon SK. Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort. Open Forum Infect Dis. 2025 Mar 21;12(4):ofaf177. doi: 10.1093/ofid/ofaf177. PMID: 40207047; PMCID: PMC11979587.

Tags: abacavir, antiretroviral therapy, Infectious Diseases, major adverse cardiovascular events, Publications, REPRIEVE, Tenofovir

Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands

Nerguizian D, Wei Z, Aldrovandi G, Currier J, Eron J, Fischer W, Gandhi R, Hamill M, Hosey L, Javan A, McCarthy C, Nachman S, Valiyaparambil[...]

Histone deacetylase 7 mediates lipopolysaccharide-inducible mitochondrial fission in macrophages

Abrol R, Afroz SF, Curson JEB, Raven KD, Gupta KD, Gunther KS, Jones A, Reid RC, Xiong Z, Gunter JH, Engel JA, Engwerda CR, Blumenthal[...]

Patterns of sexual minority men’s lifestyle and healthcare related activity spaces in Los Angeles

Cassels S, Reid SC, Murray AT, Kaloper S, Wang V, Shoptaw S, Gorbach P. Patterns of sexual minority men's lifestyle and healthcare related activity spaces[...]